全文获取类型
收费全文 | 4660篇 |
免费 | 209篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 69篇 |
妇产科学 | 225篇 |
基础医学 | 536篇 |
口腔科学 | 16篇 |
临床医学 | 250篇 |
内科学 | 888篇 |
皮肤病学 | 598篇 |
神经病学 | 191篇 |
特种医学 | 48篇 |
外科学 | 327篇 |
综合类 | 440篇 |
预防医学 | 273篇 |
眼科学 | 11篇 |
药学 | 604篇 |
1篇 | |
中国医学 | 160篇 |
肿瘤学 | 247篇 |
出版年
2023年 | 55篇 |
2022年 | 102篇 |
2021年 | 137篇 |
2020年 | 131篇 |
2019年 | 104篇 |
2018年 | 125篇 |
2017年 | 124篇 |
2016年 | 144篇 |
2015年 | 145篇 |
2014年 | 276篇 |
2013年 | 355篇 |
2012年 | 236篇 |
2011年 | 280篇 |
2010年 | 218篇 |
2009年 | 234篇 |
2008年 | 231篇 |
2007年 | 235篇 |
2006年 | 196篇 |
2005年 | 171篇 |
2004年 | 162篇 |
2003年 | 113篇 |
2002年 | 119篇 |
2001年 | 110篇 |
2000年 | 90篇 |
1999年 | 75篇 |
1998年 | 62篇 |
1997年 | 56篇 |
1996年 | 55篇 |
1995年 | 55篇 |
1994年 | 48篇 |
1993年 | 27篇 |
1992年 | 44篇 |
1991年 | 32篇 |
1990年 | 24篇 |
1989年 | 19篇 |
1988年 | 19篇 |
1986年 | 14篇 |
1985年 | 32篇 |
1984年 | 30篇 |
1983年 | 17篇 |
1982年 | 19篇 |
1981年 | 15篇 |
1980年 | 17篇 |
1979年 | 12篇 |
1976年 | 18篇 |
1975年 | 18篇 |
1974年 | 15篇 |
1973年 | 17篇 |
1972年 | 12篇 |
1971年 | 12篇 |
排序方式: 共有4898条查询结果,搜索用时 171 毫秒
1.
BackgroundPrior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacterized.MethodsUsing the SEER 18 registries (2000–2017), we examined the temporal trend of the incidence of HGGs and BC. The standardized incidence ratio was calculated to assess the risk of subsequent HGG in BC patients.ResultsDuring the study period, the incidence of BC and HGGs remained comparable for men and women. Among 976,134 patients with BC, we found a decreased incidence of HGGs in females, but not in males. Female BC patients with hormone receptor-positive disease were at a lower risk of developing glioblastoma and anaplastic astrocytoma.ConclusionOur study findings allude to the protective role of hormone exposure in the development of HGGs, which may lead to the development of therapies targeting hormonal pathways. 相似文献
2.
3.
4.
5.
BackgroundIllicit drug use and associated disease burden are estimated to have increased over the past few decades, but large gaps remain in our knowledge of the extent of use of these drugs, and especially the extent of problem or dependent use, hampering confident cross-national comparisons. The World Mental Health (WMH) Surveys Initiative involves a standardised method for assessing mental and substance use disorders via structured diagnostic interviews in representative community samples of adults. We conducted cross-national comparisons of the prevalence and correlates of drug use disorders (DUDs) in countries of varied economic, social and cultural nature.Methods and findingsDSM-IV DUDs were assessed in 27 WMH surveys in 25 countries. Across surveys, the prevalence of lifetime DUD was 3.5%, 0.7% in the past year. Lifetime DUD prevalence increased with country income: 0.9% in low/lower-middle income countries, 2.5% in upper-middle income countries, 4.8% in high-income countries. Significant differences in 12-month prevalence of DUDs were found across country in income groups in the entire cohort, but not when limited to users. DUDs were more common among men than women and younger than older respondents. Among those with a DUD and at least one other mental disorder, onset of the DUD was usually preceded by the ‘other’ mental disorder.ConclusionsSubstantial cross-national differences in DUD prevalence were found, reflecting myriad social, environmental, legal and other influences. Nonetheless, patterns of course and correlates of DUDs were strikingly consistent. These findings provide foundational data on country-level comparisons of DUDs. 相似文献
6.
《Clinical breast cancer》2020,20(2):89-97
BackgroundTherapies targeting estrogen receptor signaling are standard for patients with hormone receptor (HR)-positive (HR+) metastatic breast cancer (MBC). Dysregulation of the phosphoinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway is associated with treatment resistance. Addition of the mTOR inhibitor, everolimus, to exemestane doubled progression-free survival (PFS) in HR+/HER2− MBC patients whose disease had previously progressed during endocrine therapy. In this phase II study, we used everolimus in addition to the most recent endocrine therapy during which a patient's disease progressed, in an attempt to restore and extend the benefit of the antiestrogen therapy in patients with HR+/HER2− MBC.Patients and MethodsPatients with HR+ MBC who progressed on antiestrogen therapy received everolimus (10 mg orally daily) in combination with the antiestrogen therapy most recently administered. Treatment was administered in 4-week cycles and continued until disease progression or unacceptable toxicity. Blood and archival tumor specimens were collected for VeriStrat (Biodesix, Inc) and Foundation One (Foundation Medicine) assays, respectively. Accrual of 42 evaluable patients allowed detection of improvement in median PFS from 2.8 months (expected with hormonal treatment alone) to 5 months (power 80%, α = 5%).ResultsForty-seven patients were enrolled and treated. After a median follow-up of 22.2 months, median PFS was 6.6 months. Secondary efficacy end points included: overall response rate, 6%; clinical benefit rate, 40%; and median overall survival, 21.1 months. No unexpected toxicity was observed. Efficacy could not be correlated with PI3K/AKT/mTOR alterations or VeriStrat (Biodesix, Inc) prognostic signatures.ConclusionAfter progression during antiestrogen therapy, the addition of everolimus, without changing the hormonal therapy, resulted in a median PFS of 6.6 months, suggesting efficacy in patients with HR+/HER2− MBC. 相似文献
7.
《Clinical breast cancer》2020,20(1):e27-e35
BackgroundEvidence-based timeliness benchmarks have been established to assess quality of breast cancer care, as delays in treatment are associated with poor clinical outcomes. However, few studies have evaluated how current breast cancer care meets these benchmarks and what factors may delay the timely initiation of treatment.Patients and MethodsDemographic and disease characteristics of 377 newly diagnosed patients with breast cancer who initiated treatment at Tufts Medical Center (2009-2015) were extracted from electronic medical records. Time from diagnosis to initial surgery and time from diagnosis to initiation of hormone therapy were estimated with Kaplan-Meier curves. Multivariable regression analysis was used to identify factors associated with treatment delays. Thematic analysis was performed to categorize reasons for delay.ResultsOf 319 patients who had surgery recommended as the first treatment, 248 (78%) met the 45-day benchmark (median, 28 days; 25th-75th %, 19-43). After adjusting for potential confounders, multivariable regression analysis revealed that negative hormone receptor status (odds ratio, 3.48; 95% confidence interval, 1.44-8.43) and mastectomy (odds ratio, 4.07; 95% confidence interval, 2.10-8.06) were significantly associated with delays in surgery. Delays were mostly owing to clinical complexity or logistical/financial reasons. Of 241 patients eligible for hormone therapy initiation, 232 (96%) met the 1-year benchmark (median, 147 days; 25th-75th %, 79-217).ConclusionMost patients met timeliness guidelines for surgery and initiation of hormone therapy, although risk factors for delay were identified. Knowledge of reasons for breast cancer treatment delay, including clinical complexity and logistical/financial issues, may allow targeting interventions for patients at greatest risk of care delays. 相似文献
8.
【摘要】 目的 评价度普利尤单抗治疗特应性皮炎(AD)的有效性和安全性。方法 采用回顾性研究方法,纳入2020年6月1日至2021年9月1日在北京大学第一医院皮肤科门诊外用药物控制不佳、规范使用度普利尤单抗注射治疗满16周的AD患者。收集患者基本信息以及治疗开始前、治疗第2、4、8、12、16周研究者整体评估(IGA)评分、湿疹面积及严重程度指数(EASI)评分、瘙痒数字评价量表(NRS)评分、皮肤病生活质量指数(DLQI)评分以及源自患者的湿疹评价(POEM)评分。记录治疗过程中出现的不良反应。采用Wilcoxon秩和检验对全部患者结束随访时各项评分和治疗前进行比较。结果 共纳入57例AD患者,均完成16周的注射药物治疗和随访观察。第16周时 ,患者自身IGA评分由基线4.0(4.0,5.0)分降至1.0(1.0,1.0)分(Z = 6.65,P < 0.001),EASI评分由30.0(17.2,36.0)分降至4.0(1.6,7.3)分(Z = 6.57,P < 0.001),瘙痒NRS评分由9.0(7.0,10.0)分降至1.0(0.0,1.0)分(Z = 6.59,P < 0.001),DLQI评分由15.0(11.5,20.5)分降至3.0(1.0,4.0)分(Z = 6.57,P < 0.001),POEM评分由19.0(15.5,23.0)分降至4.0(2.0,4.0)分(Z = 6.57,P < 0.001),差异均有统计学意义。5种评分16周内均呈持续下降趋势。仅2例患者出现结膜炎,无明显严重不良反应。结论 度普利尤单抗治疗AD疗效明显,且具有较好的安全性。 相似文献
9.
The optimal management in Oligometastatic (OM) breast carcinoma is not defined.ObjectivesTo identify the prognostic factors influencing OM and the effect of Locoregional treatment (LRT) on survival in OM.MethodologyPatients with ≤5 metastases and each with ≤ 5 cm size were defined as OM. Data of OM were extracted from the Institute Registry between 2012 and 2018. The impact of prognostic factors on survival was analysed by univariate and multivariate Cox regression. The Kaplan Meier survival curves were used to plot PFS and OS.ResultsThere were 170 patients with OM. The median follow-up was 61 months. Median OS was 43.3 months. The median OS was 74 months in OMD vs 22.7 months in Oligorecurrent disease (ORD) with 5year OS rate of 55.3% vs 16.5% respectively. In the multivariate analyses of OMD both Ki67 ≤ 50% and hormone therapy (HT) showed significant favourable survival outcome. While premenopausal status and HT showed significant survival benefits in ORD. The worse survival outcome in ORD could be because of their aggressive biology and deficit in LRT compared to literature review. The prognostic factors were swayed by the uneven distribution of HR status, grade and Ki67.ConclusionThe survival of OM was influenced by OMD, Ki67 ≤ 50%, premenopausal status and HT. The lesser survival rates of OM in the long term suggest the need for curative LRT to metastatic sites and primary tumor. The potential role of HT and targeted therapy with or without LRT need to be assessed in future randomised trials. 相似文献
10.